GEN Exclusives

More »

GEN News Highlights

More »
Dec 28, 2011

Even Split on OS vs. PFS As Primary Endpoint for Cancer Drug Approvals

  • As many GEN poll voters agree as disagree that the primary endpoint for approval of cancer drugs should change to progression-free survival (PFS) from overall survival (OS), with 15.8% undecided. FDA’s recent success in removing Avastin’s metastatic breast cancer (MBC) indication re-ignited a longstanding debate in drug development circles over what the primary endpoint should be. Avastin’s initial accelerated approval, in combination with paclitaxel, for MBC was based on PFS data. But last year FDA’s CDER recommended that MBC be withdrawn since subsequent studies showed only a small improvement in OS. FDA noted that Avastin’s PFS improvement was not worth the risk of associated side effects. Avastin maker Genentech and parent Roche countered that PFS should be the primary endpoint, because it could be objectively measured and because the EU recognized it as an oncology endpoint.

     


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?